Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2193-2198

  Gruber, Beata M ^a   Anuszewska, Elzbieta L ^a   Bubko, Irena ^a   Gozdzik, Aneta ^a   Priebe, Waldemar ^b   Fokt, Izabela ^b  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Anthracyclines; Apoptosis; Topo II poison

Indexed keywords

ANNAMYCIN; ANTHRACYCLINE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG; VINBLASTINE; WP 903;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG RESISTANCE; FLUORESCENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DOXORUBICIN; FEMALE; HELA CELLS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; UTERINE CERVICAL NEOPLASMS;

EID: 21344456975     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wu S, Ko YS, Teng MS, Ko YL, Hsu LA, Hsueh C, Chou YY, Liew CC and Lee YS: Adriamycin-induced cardiomyocyte and endothelial cell apoptosis in vitro. J Mol Cell Cardiol 34: 1595-1607, 2002 .
2. Nielsen D, Maare Ch and Skovsgaard T: Cellular resistance to anthracyclines. Gen Pharm 27: 251-255, 1996.
3. Turley H, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson, Gatter K and Harris AL: The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75: 1340-1346, 1997.
4. Nakamura K et al: A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo. Cancer Sci 94: 119-124, 2003.
5. Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ and Di Leo A: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 24: 201-209, 2004.
6. Topcu Z: DNA topoisomerases as targets for anticancer drugs. Review article. J Clin Pharm Ther 26: 405-416, 2001.
7. Godard T, Deslandes E, Sichel F, Poul J-M and Gauduchon P: Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 520: 47-56, 2003.
8. Beck WT, Kim R and Chen M: Novel actions of inhibitors of DNA topoisomerase II in drug- resistant tumor cells. Cancer Chemother Pharmacol 34(Suppl): S14-S18, 1994.
9. Tsai-Kun Li and Liu LF: Tumor cell death induced by topoisomerase- targeting drugs. Annu Rev Pharmacol Toxicol 41: 53-77, 2001.
10. Den Boer ML, Pieters R and Veerman AJP: Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Review. Leukemia 12: 1657-1670, 1998.
11. Di Leo A and Isola J: Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at end of the beginning? Clin Breast Cancer 4: 179-186, 2003.
12. Lage H and Dietel M: Multiple mechanisms confer different drug- resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 128: 349-357, 2002.
13. Montaudon D, Pourquier P, Denois F, De Tinguy-Moreaud and Lagarde P: Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells. Eur J Biochem 245: 307-315, 1997.
14. Fedier A, Moawad A, Haller U and Fink D: p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase. Int J Oncol 23: 1431-1437, 2003.
15. Gruber BM and Anuszewska EL: Influence of vitamin D3 metabolites on cell proliferation and cytotoxicity of adriamycin in human normal and neoplastic cells. Toxicol In Vitro 16: 663-667, 2002.
16. Gruber BM, Anuszewska EL and Skierski J: Activation of programmed cell death (apoptosis) by adriamycin in human neoplastic cells. Mutat Res 484: 87-93, 2001.
17. Binaschi M, Capranico G, Dal Bo L and Zunino F: Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracycline with different sequence specificity. Mol Pharmacol 51: 1053-1059, 1997.
18. Gewirtz DA: A critical evaluation of the mechanism of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
19. Ling Y-H, Priebe W and Perez-Soler R: Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 53: 1845-1852, 1993.
20. Evans CD, Mirski SE, Danks MK and Cole SP: Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line. Cancer Chemother Pharmacol 34: 242-248, 1994.
21. Park K, Lim S and Han S: Topoisomerase II-alpha (topo II) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39: 631-634, 2003.
22. de Jong S, Zijlstra JG, de Vries EG and Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309, 1990.
23. De Boer RA, van Veldhuisen DJ, van der Wijk J, Brouwer RM, de Jonge N, Cole GM and Suurmeijer AJ: Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patient with chronic heart failure. J Card Fail 6: 330-337, 2000.
24. Ling Y-H, Priebe W, Yang L-Y, Burke TG, Pommier Y and Perez-Soler R: In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res 53: 1583-1589, 1993.
25. Gariboldi MB et al: Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int J Oncol 22: 1057-1064, 2003.
26. Masquelier M, Zhou QF, Gruber A and Vitols S: Relationship between daunorubicin concentration and apoptosis induction in leukemic cells. Biochem Pharmacol 67: 1047-56, 2004.
27. Bellarosa D, Ciucci A, Bullo A, Nardelli F, Manzini S, Maggi CA and Goso C: Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines. J Pharmacol Exp Ther 296: 276-283, 2001.
28. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM and Priebe W: WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21: 3777-3784, 2001.
29. Huigsloot M, Tijdens IB, Mulder GJ and van de Water B: Differential regulation of phosphatidylserine externalization and DNA fragmentation by caspases in anticancer drug-induced apoptosis of rat mammary adenocarcinoma MTLn3 cells. Biochem Pharmacol 62: 1087-1097, 2001.
30. Holleman A, den Boer ML, Kazemier KM, Janka-Schaub GE and Pieter R: Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. Blood 102: 4541-4546, 2003.
31. Hopkins-Donaldson S, Yan P, Bourloyd KB, Muhlethaler A, Bodmer JL and Gross N: Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells. Oncogene 21: 6132-6137, 2002.
32. Yeung S-ChJ, Xu G, Pan J, Christgen M and Bamiagis A: Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 60: 650-656, 2000.